β¨ Medicine Distribution Consents
4 APRIL
NEW ZEALAND GAZETTE
839
Dosage Form:
Solution for infusion
New Zealand Sponsor:
Baxter Healthcare Limited
Manufacturer:
Clintec Parenteral S.A., Zone Industrielle dβAmilly, Montargis, France
Product:
Ritalin LA
Active Ingredient:
Methylphenidate hydrochloride 20mg
Dosage Form:
Modified release capsule
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Elan Holdings, Gainesville, Georgia, United States of America
Product:
Ritalin LA
Active Ingredient:
Methylphenidate hydrochloride 30mg
Dosage Form:
Modified release capsule
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Elan Holdings, Gainesville, Georgia, United States of America
Product:
Ritalin LA
Active Ingredient:
Methylphenidate hydrochloride 40mg
Dosage Form:
Modified release capsule
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Elan Holdings, Gainesville, Georgia, United States of America
Dated this 28th day of March 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go2244
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
Product:
Cancidas
Active Ingredient:
Caspofungin acetate 57.8mg equivalent to 50mg caspofungin anhydrous free base
Dosage Form:
Powder for concentrate for infusion
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America
Product:
Cancidas
Active Ingredient:
Caspofungin acetate 60.6mg equivalent to 50mg caspofungin anhydrous free base
Dosage Form:
Powder for infusion
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America
Product:
Cancidas
Active Ingredient:
Caspofungin acetate 83.9mg equivalent to 70mg caspofungin anhydrous free base
Dosage Form:
Powder for infusion
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America
Product:
NovoMix 30 NovoLet
Active Ingredient:
Insulin aspart 100IU/mL
Dosage Form:
Suspension for injection
New Zealand Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturer:
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Product:
NovoMix 30 Penfill
Active Ingredient:
Insulin aspart 100IU/mL
Dosage Form:
Suspension for injection
New Zealand Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturer:
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Dated this 28th day of March 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go2245
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 31
Gazette.govt.nz —
NZ Gazette 2002, No 31
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of New Medicine Primene
(continued from previous page)
π₯ Health & Social WelfareMedicines, Consent, Primene, Baxter Healthcare Limited
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare28 March 2002
Medicines, Consent, Cancidas, NovoMix 30
- G. R. Boyd, Chief Advisor, Safety and Regulation